Metabolic dysfunction–associated steatohepatitis (MASH) is a form of liver disease that can progress ... to evaluate the GLP-1 receptor agonist semaglutide in patients with MASH and stage ...

Individuals with diabetes and hypertension are especially at risk and should undergo screening for NAFLD (Non-Alcoholic Fatty ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

A recommended 150 minutes per week at moderate intensity can help reduce liver inflammation and rid the organ of fat. Antioxidants and other compounds in coffee (even decaf) can help protect against ...

Discover a recent study where the authors propose a strategic push to double the diagnostic rate of at-risk MASH by 2030.

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

India is facing a silent epidemic of non-alcoholic fatty liver disease, especially affecting young people. Around 1 to 3 ...

A South Korean biotech’s GLP-1 candidate has reduced liver fat in patients with metabolic dysfunction-associated ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

"Whereas semaglutide works by activating receptors ... we will choose the GLP-1 that is proven to work best for liver disease," she said. Looking ahead, the researchers plan to investigate new ...

Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

Head of the Metabolic Neuroscience Laboratory, investigates the brain ‘goo’ behind obesity and Type-2 diabetes - and how we ...